A new 111In-bleomycin complex for combined radiotherapy and chemotherapy.
Six days after tumor transplantation three daily intraperitoneal doses of 0.9% NaCl, bleomycin (BLM), or a new 111In-bleomycin complex (BLMC, 15 microCi/g body weight) were administered to glioma-bearing mice. After therapy, tumors in mice treated with 111In-BLMC were smaller than those treated with BLM. Sixteen days after the first injection tumor size for 111In-BLMC-treated mice was 560 (240-1,030) mm3, 1,980 (1,400-3,290) mm3 for BLM (P less than 0.025), and 4,830 (2,580-9,180) mm3 for NaCl (0.1 less than P less than 0.2). Thirteen days after tumor transplantation glioma-bearing mice received single intratumor injection of 0.9% NaCl, BLM, or 111In-BLMC (1.5 mCi, carried by 0.5 mg BLM/g tumor weight). The average tumor size for 111In-BLMC was smaller than that for BLM by a factor of 2.5-3.7. Host weights for these two groups were similar, and morphologic abnormalities were not found in kidney or liver.
D Y
DY
Hou
H
H
Hoch
G S
GS
Johnston
K C
KC
Tsou
A E
AE
Jones
R J
RJ
Farkas
E E
EE
Miller
S M
SM
Larson
D000818:Animals; D001761:Bleomycin / Q000008:administration & dosage / Q000627:therapeutic use* / Q000031:analogs & derivatives; D001835:Body Weight; D001918:Brachytherapy / Q000379:methods*; D003131:Combined Modality Therapy; D004353:Drug Evaluation, Preclinical; D005121:Extremities; D005910:Glioma / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D007204:Indium / Q000008:administration & dosage / Q000627:therapeutic use*; D007274:Injections, Intraperitoneal; D007553:Isotope Labeling; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009336:Necrosis / Q000473:pathology; D009942:Organometallic Compounds; D011868:Radioisotopes / Q000008:administration & dosage / Q000627:therapeutic use*
D009942:Organometallic Compounds; D011868:Radioisotopes; C047120:indium-bleomycin; D007204:Indium; D001761:Bleomycin